XLRP RPGR 的长期随访基因治疗研究
在对成人和儿童 X 连锁色素性视网膜炎进行基因治疗的重组腺相关病毒载体 (AAV2-RPGR) 的开放标签、多中心、I/II 期剂量递增试验后对参与者进行长期随访研究由于视网膜色素变性 GTP 酶调节剂 (RPGR) 的缺陷
This is a long-term follow-up study assessing safety of patients for up to 60 months following advanced therapy investigational medicinal product (ATIMP) AAV5-hRKp.RPGR vector in participants with XLRP caused by mutations in RPGR.
研究概览
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- Massachusetts Eye and Ear Infirmary
-
-
Michigan
-
Ann Arbor、Michigan、美国、48105
- Univ of Michigan Medical Center
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15213
- University of Pittsburgh Medical Center
-
-
-
-
-
Leeds、英国、LS9 7TF
- Leeds Teaching Hospitals NHS Trust
-
London、英国、EC1V 9EL
- Moorfields Eye Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Males receiving AAV5-hRKp.RPGR in the MGT009 study
描述
Inclusion Criteria:
- Received AAV5-hRKp.RPGR in the MGT009 Study
Exclusion Criteria:
- Unwilling or unable to meet with the requirements of the study
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Follow up cohort
no intervention follow up study |
Participants will not receive any intervention in this study. Participants from the retrospective (MGT009-NCT03252847) study will be follow-up. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Assess the Longer-term Safety of AAV5-hRKp.RPGR Administered to Participants
大体时间:60 Months
|
Longer-term safety of subretinal AAV5-hRKp.RPGR administered to participants will be reported. |
60 Months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Functional Vision of Walk Time in Vision-guided Mobility Assessment (VMA)
大体时间:Up to 60 Months
|
Change in functional vision of walk time after treatment administration in VMA (Version 1.0) will be reported. |
Up to 60 Months
|
|
Change in Functional Vision of Low Luminance Questionnaire (LLQ) Domain Scores in Patient Reported Outcome (PRO)
大体时间:Up to 60 Months
|
Change in functional vision of LLQ domain scores in PRO will be reported. The instrument is scored by domain, computed by scaling individual items from 0 to 100 and then averaging the individual items for each domain. A higher score reflects higher functional level. |
Up to 60 Months
|
|
Change in Best Corrected Visual Acuity (BCVA) Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart Letter Score
大体时间:Up to 60 Months
|
The longer-term efficacy of AAV5-hRKp.RPGR in change in BCVA using ETDRS chart letter score will be reported. |
Up to 60 Months
|
|
Change in Low Luminance Visual Acuity (LLVA) as Assessed by ETDRS Chart Under Low Luminance Conditions
大体时间:Up to 60 Months
|
Change in LLVA as assessed by ETDRS chart under low luminance conditions will be reported. |
Up to 60 Months
|
|
Change in Mean Retinal Sensitivity Within the Central 10 Degree Visual Field Excluding Scotoma (MRS10) in Static Perimetry
大体时间:Up to 60 months
|
Change in mean retinal sensitivity within the central 10 degrees excluding scotoma (MRS10) in static perimetry will be reported. |
Up to 60 months
|
|
Change In Retinal Sensitivity by Pointwise Comparison of Data in Static Perimetry Within the Full Visual Field
大体时间:Up to 60 months
|
Change in retinal sensitivity by pointwise comparison of data in static perimetry within the full visual field will be reported. |
Up to 60 months
|
|
Change In Retinal Sensitivity by Pointwise Comparison of Data in Static Perimetry Within the Central 30 Degrees Visual Field
大体时间:Up to 60 months
|
Change in retinal sensitivity by pointwise comparison of data in static perimetry within the Central 30 Degrees visual field will be reported. |
Up to 60 months
|
|
Change in Mean Retinal Sensitivity Within the Full Visual Field Excluding Scotoma (MRS90) in Static Perimetry
大体时间:Up to 60 months
|
Change in mean retinal sensitivity within the full visual field excluding scotoma (MRS90) in static perimetry will be reported. |
Up to 60 months
|
合作者和调查者
调查人员
- 研究主任:Study Director、MeiraGTx Ocular UK Ltd
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- MGT010
- 2018 (美国 NIH 拨款/合同)
- 2018-000425-31 (EudraCT编号)
- MGT010 (其他标识符:MeiraGTx Ocular UK Ltd)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.